Endoscopic Ultrasound Radiofrequency Ablation and Immunotherapy Pembrolizumab for Locally Advanced Unresectable and Metastatic Pancreatic Duct Adenocarcinoma

NCT06831136 · clinicaltrials.gov ↗

PHASE2

Phase

RECRUITING

Status

24

Enrollment

OTHER

Sponsor class

Conditions

Pancreatic Ductal Adenocarcinoma

Interventions

DRUG: Neoadjuvant Chemotherapy (NAC)
DRUG: Immunotherapy (pembrolizumab)
DEVICE: Endoscopic ultrasound (EUS)-guided radiofrequency ablation (RFA)

Sponsor

The University of Texas Health Science Center, Houston